Vision Disorders and Phosphodiesterase Type 5 Inhibitors: A Review of the Evidence to Date

ISSN： 0114-5916

Source： Drug Safety, Vol.32, Iss.1, 2009-01, pp. : 1-18

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Phosphodiesterase Type 5 Inhibitors: Unmet Needs

Current Pharmaceutical Design, Vol. 15, Iss. 30, 2009-10 ,pp. : 3476-3485

Bentham Science Publishers

Access to resources Recommend Favorite

Phosphodiesterase Type 5 Inhibitor Abuse: A Critical Review

Current Drug Abuse Reviews, Vol. 4, Iss. 2, 2011-06 ,pp. : 87-94

Bentham Science Publishers

Access to resources Recommend Favorite

Phosphodiesterase type 5 (PDE5) inhibitors for the treatment of erectile dysfunction

By Dorsey Philip Keel Christopher Klavens Meghan Hellstrom Wayne JG

Expert Opinion on Pharmacotherapy, Vol. 11, Iss. 7, 2010-05 ,pp. : 1109-1122

Informa Healthcare

Access to resources Recommend Favorite

Phosphodiesterase Type 5 Inhibitors for High-Altitude Pulmonary Hypertension: A Meta-Analysis

By Jin Bo Luo Xin-Ping Ni Huan-Chun Shi Hai-Ming

Clinical Drug Investigation, Vol. 30, Iss. 4, 2010-04 ,pp. : 259-265

Adis International

Access to resources Recommend Favorite

An update on pharmacological treatment of erectile dysfunction with phosphodiesterase type 5 inhibitors

By Bruzziches Roberto

Expert Opinion on Pharmacotherapy, Vol. 14, Iss. 10, 2013-07 ,pp. : 1333-1344

Informa Healthcare

Access to resources Recommend Favorite